IP Library › Granted Patent US 12,358,957
Granted Patent B2
US 12,358,957 · App. 17/499,753 · Granted Jul 15, 2025

Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity

Inventor: Jones Bryan (Cambridgeshire, GB)
Assignee: Revolo Biotherapeutics Limited
C07K14/35A61K45/06A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,957
App. No.
17/499,753
Granted
Jul 15, 2025
Kind
B2
Abstract

The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.

Claims (20)

1. A method for acute treatment of atopic dermatitis or allergic skin hypersensitivity in a non-human mammalian subject, the method comprising the steps of:

(a) administering to a non-human mammalian subject in need thereof one or more doses of an effective amount of a peptide molecule, the peptide molecule comprising an amino acid sequence as set forth in SEQ ID NO: 1, or having more than 95% identity to the amino acid sequence as set forth in SEQ ID NO: 1, wherein the peptide molecule is less than 50 amino acid residues in length, and wherein the acute treatment method causes remission of atopic dermatitis or allergic skin hypersensitivity of the non-human mammalian subject; and

(b) stopping the administration of the peptide molecule upon remission of the atopic dermatitis or allergic skin hypersensitivity.

2. The method of claim 1 , wherein the peptide molecule is less than 40 amino acid residues in length.

3. The method of claim 1 , wherein the peptide molecule consists of the amino acid sequence of SEQ ID NO: 1.

4. The method of claim 1 , wherein remission comprises reduction, alleviation or elimination of one or more symptoms of atopic dermatitis or allergic skin hypersensitivity.

5. The method of claim 1 , wherein remission comprises reduction, alleviation or elimination of one or more symptoms of atopic dermatitis or allergic skin hypersensitivity for a period of time which significantly exceeds a plasma pharmacokinetic half-life of the peptide molecule.

6. The method of claim 1 , wherein remission is maintained when a plasma concentration of the peptide molecule is below a lower limit of quantification.

7. The method of claim 6 , wherein the plasma concentration is below the lower limit of quantification at circulating levels of less than 20 ng/ml.

8. The method of claim 6 , wherein remission of atopic dermatitis or allergic skin hypersensitivity is for a period of at least 7 days after the plasma concentration is below the lower limit of quantification.

9. The method of claim 1 , wherein remission of atopic dermatitis or allergic skin hypersensitivity is for a period of at least 7 days after administration of a final dose of the peptide molecule.

10. The method of claim 9 , wherein remission of atopic dermatitis or allergic skin hypersensitivity is for a period of at least 14 days after administration of the final dose of the peptide molecule.

11. The method of claim 10 , wherein remission of atopic dermatitis or allergic skin hypersensitivity is for a period of at least 28 days after administration of the final dose of the peptide molecule.

12. The method of claim 11 , wherein remission of atopic dermatitis or allergic skin hypersensitivity is for a period of at least 6 months after administration of the final dose of the peptide molecule.

13. The method of claim 1 , wherein a single dose of the peptide molecule is administered to a canine subject.

14. The method of claim 1 , wherein a single dose of the peptide molecule is administered to an equine subject.

15. The method of claim 1 , wherein a single dose of the peptide molecule is administered to an equine subject for treatment of allergic skin hypersensitivity.

16. The method of claim 1 , wherein the subject is further administered one or more additional therapeutic agents.

17. The method of claim 16 , wherein the one or more therapeutic agents is selected from the group consisting of disease modifying agents, analgesics, anti-inflammatory agents, anti-allergic drugs, allergen immunotherapeutic agents, antivirals, antibiotics, antibodies and steroids.

18. The method of claim 1 , wherein the level of one or more of TNF-alpha, IL-Ib, IFN-gamma, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IL-23, KC (CCL-1), Eotaxin (CCL-11), TARC (CCL-17) and/or MDC (CCL-22) are decreased following administration of SEQ ID NO:1 as compared to prior to administration.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2022
From: BRYAN, JONES
To: REVOLO BIOTHERAPEUTICS LIMITED
Reel/Frame 059226/0823 →
Priority Claims (1)
GB 1700555 · Jan 12, 2017 · national
Continuity (3)
Continuation In Part 17397816 · Aug 9, 2021
Division 16476058
Related Publication 20220024995A1 · Jan 27, 2022
References Cited (59)
US 9085632B2 · Coates et al. · 2015 [cited by applicant]
US 11479585B2 · Lightfoot et al. · 2022 [cited by applicant]
US 11834477B2 · Bryan · 2023 [cited by examiner]
US 11834478B2 · Lightfoot · 2023 [cited by examiner]
US 20060217407A1 · Redkar et al. · 2006 [cited by applicant]
US 20110052616A1 · Coates et al. · 2011 [cited by applicant]
US 20140341932A1 · Coates et al. · 2014 [cited by applicant]
US 20200369750A1 · Kawakami et al. · 2020 [cited by applicant]
US 20210230233A1 · Lightfoot et al. · 2021 [cited by applicant]
US 20210371475A1 · Bryan · 2021 [cited by applicant]
US 20220281929A1 · Lightfoot et al. · 2022 [cited by applicant]
CN 1735427A · 2006 [cited by applicant]
CN 101965361A · 2011 [cited by applicant]
CN 102573896A · 2012 [cited by applicant]
JP 2004513925A · 2004 [cited by applicant]
JP 2007503382A · 2007 [cited by applicant]
JP 2010502765A · 2010 [cited by applicant]
JP 2011513215A · 2011 [cited by applicant]
JP 2013510094A · 2013 [cited by applicant]
JP 2014532395A · 2014 [cited by applicant]
JP 2020504161A · 2020 [cited by applicant]
JP 7252895B2 · 2023 [cited by applicant]
WO 0240037A2 · 2002 [cited by applicant]
WO 0240038A2 · 2002 [cited by applicant]
WO 2005021043A2 · 2005 [cited by applicant]
WO 2008033820A2 · 2008 [cited by applicant]
WO 2009106819A2 · 2009 [cited by applicant]
WO 2011057078A2 · 2011 [cited by applicant]
WO 2013057499A1 · 2013 [cited by applicant]
WO 2018130834A1 · 2018 [cited by applicant]
WO 2018130835A1 · 2018 [cited by applicant]
Fautrel, et al., “De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?”, Best Practice & Research Clinical Rheumatology, vol. 29, 2015, 16 pages. [cited by applicant]
Klarenbeek, et al., “Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the Best study”, Annals of Rheumatic diseases, vol. 70, 2011, pp. 315-319. [cited by applicant]
Schett, et al., “Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions”, Annals of Rheumatic Diseases, vol. 75, 2016, pp. 1428-1437. [cited by applicant]
Heidari, Behzad, “Rheumatoid Arthritis: Early Diagnosis and Treatment Outcomes”, Caspian Journal of Internal Medicine, vol. 2, Issue 1, 2011, pp. 161-170. [cited by applicant]
Perng, Diahn-Warng, et al., “Characteristics of Airway Inflammation and Bronchodilator Reversibility in COPD”, Chest, 126, vol. 2, Aug. 2004, pp. 375-381. [cited by applicant]
Ramani, Thulasi, et al., “Cytokines: The Good, the Bad, and the Deadly”, International Journal of Toxicology, vol. 34, Issue 4, 2015, pp. 355-365. [cited by applicant]
“International Search Report and Written Opinion received for PCT Patent Application No. PCT/GB2018/050073 mailed Jun. 22, 2018”, 22 pages. [cited by applicant]
Brightling , “Clinical trial research in focus: do trials prepare us to deliver precision medicine in those with severe asthma?”, Lancet Respiratory Medicine, vol. 05, Feb. 2017, pp. 92-95. [cited by applicant]
Coin I , “Solid-phase peptide synthesis: from standard procedures to the synthesis”, Nature Protocols, No. 2, vol. 12, 2007, pp. 3247-3256. [cited by applicant]
Derossi D , et al., “Trojan peptides: the penetratin system for intracellular delivery”, Trends Cell Biol., vol. 8(2), 1998, pp. 84-87. [cited by applicant]
Fields, G.B. , et al., “Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids”, Int. J. Peptide Protein Res., 35(3),, 1990, pp. 161-214. [cited by applicant]
Hein J. , “Unified approach to alignment and phylogenies”, Methods Enzymology, vol. 183,, 1990, pp. 626-645. [cited by applicant]
Jones, J H , “A short guide to abbreviations and their use in peptide science”, Journal of Peptide Science, vol. 5, No. 11, 1999, pp. 465-471. [cited by applicant]
Juniper EF , et al., “Development and validation of a questionnaire to measure asthma control”, Eur Respir J, 14(4), 1999, pp. 902-907. [cited by applicant]
Laskey, RA , et al., “Nucleosomes are assembled by an acidic polypeptide which binds histones and transfers them to DNA”, Nature, 275, 1978, pp. 416-420. [cited by applicant]
Mcdowell, R S , et al., “Structural studies of potent constrained RGD peptides”, J. Amer. Chem. Soc., vol. 114(24), 1992, pp. 9245-9253. [cited by applicant]
Page , et al., “PIN201104, A Peptide Derived from Mycobacterium Tuberculosis Chaperonin 60.1 Shows Prolonged Modulation of Allergic Inflammation in Murine Lungs”, American Journal of Respiratory and Critical Care Medici… [cited by applicant]
Pavord , et al., “After asthma: redefining airways diseases”, Lancet, vol. 391, No. 10118, Sep. 11, 2017, pp. 350-400. [cited by applicant]
Ranford, J C , et al., “Chaperonins are cell-signalling proteins: the unfolding biology of molecular chaperones”, Expert Rev Mol Med, vol. 2, No. 8, Sep. 15, 2000, pp. 1-17. [cited by applicant]
Ranson , et al., “Review Article: Chaperones”, Biochem. J, vol. 333, 1998, pp. 233-242. [cited by applicant]
Saragovi, H U , et al., “Loops and Secondary Structure Mimetics: Development and Applications in Basic Science and Rational Drug Design”, Biotechnology, vol. 10, 1992, pp. 773-778. [cited by applicant]
Thompson, J D , et al., “CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice”, Nucleic Acids Research, vol… [cited by applicant]
Zugel, U , et al., “Role of heat shock polypeptides in protection from and pathogenesis of infectious diseases”, Clinical Microbiology Review, vol. 12, No. 1, 1999, pp. 19-39. [cited by applicant]
International Search Report and Written Opinion for PCT Patent Application No. PCT/IB2023/000083, mailed Aug. 17, 2023, 11 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Patent Application No. PCT/GB2023/051282, mailed Jun. 23, 2023, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Patent Application No. PCT/IB2024/000197, mailed Sep. 23, 2024, 16 pages. [cited by applicant]
Jaradat, “Thirteen Decades of Peptide Synthesis: Key Developments in Solid Phase Peptide Synthesis and Amide Bond Formation Utilized in Peptide Ligation,” Amino Acids, 50:39-68 (2018). [cited by applicant]
Kong, et al., “Suppression of neovascularization and experimental arthritis by D-form of anti-fit-1 peptide conjugated with mini-PEG™,” Angiogenesis, 14:431-442 (2011). [cited by applicant]